ImmunityBio Quarterly Income Statements Chart
Quarterly
|
Annual
ImmunityBio Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenue | 40,000 | 139,000 | 82,000 | 41,000 | 360,000 | 73,000 | 118,000 | 35,000 | 14,000 | 390,000 | 66,000 | 339,000 | 139,000 | 21,000 | 68,000 | 1,000 | 21,000 | 9,000 | 12,000 | 17,000 | 5,000 | 7,000 | 31,000 | 4,000 | 5,000 | 12,000 | 8,000 | 14,000 | 11,000 | 14,000 | 12,000 | 12,000 | 6,000 | 14,000 | 10,000 | 91,000 | |||||
| yoy | -88.89% | 90.41% | -30.51% | 17.14% | 2471.43% | -81.28% | 78.79% | -89.68% | -89.93% | 1757.14% | -2.94% | 33800.00% | 561.90% | 133.33% | 466.67% | -94.12% | 320.00% | 28.57% | -61.29% | 325.00% | 0.00% | -41.67% | 287.50% | -71.43% | -54.55% | -14.29% | -33.33% | 16.67% | 83.33% | 0.00% | 20.00% | -86.81% | |||||||||
| qoq | -71.22% | 69.51% | 100.00% | -88.61% | 393.15% | -38.14% | 237.14% | 150.00% | -96.41% | 490.91% | -80.53% | 143.88% | 561.90% | -69.12% | 6700.00% | -95.24% | 133.33% | -25.00% | -29.41% | 240.00% | -28.57% | -77.42% | 675.00% | -20.00% | -58.33% | 50.00% | -42.86% | 27.27% | -21.43% | 16.67% | 0.00% | 100.00% | -57.14% | 40.00% | -89.01% | ||||||
| product revenue | 26,421,000 | 16,509,000 | 7,206,000 | 5,954,000 | 990,000 | ||||||||||||||||||||||||||||||||||||
| other revenues | 4,000 | 8,000 | 346,000 | 152,000 | 57,000 | ||||||||||||||||||||||||||||||||||||
| total revenue | 26,425,000 | 16,517,000 | 7,552,000 | 6,106,000 | 1,047,000 | ||||||||||||||||||||||||||||||||||||
| operating costs and expenses | |||||||||||||||||||||||||||||||||||||||||
| cost of sales | 136,000 | 58,000 | |||||||||||||||||||||||||||||||||||||||
| gross profit | |||||||||||||||||||||||||||||||||||||||||
| yoy | |||||||||||||||||||||||||||||||||||||||||
| qoq | |||||||||||||||||||||||||||||||||||||||||
| gross margin % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |||||
| research and development | 52,430,000 | 45,976,000 | 35,221,000 | 50,443,000 | 51,129,000 | 53,351,000 | 51,532,000 | 48,402,000 | 53,168,000 | 79,264,000 | 58,077,000 | 71,612,000 | 63,082,000 | 55,378,000 | 51,753,000 | 49,277,000 | 53,800,000 | 41,128,000 | 20,256,000 | 17,284,000 | 13,709,000 | 13,234,000 | 12,004,000 | 12,052,000 | 13,131,000 | 12,598,000 | 12,480,000 | 14,559,000 | 14,688,000 | 13,991,000 | 12,021,000 | 11,069,000 | 9,706,000 | 9,248,000 | 9,445,000 | 8,364,000 | 6,389,000 | 4,944,000 | 5,106,000 | 3,950,000 | 1,745,000 |
| research and development – related parties | 2,806,000 | 2,258,000 | |||||||||||||||||||||||||||||||||||||||
| selling, general and administrative | 41,862,000 | 31,977,000 | 41,731,000 | 35,916,000 | 49,251,000 | 41,885,000 | 33,110,000 | 31,816,000 | 32,018,000 | 32,676,000 | 26,215,000 | 19,310,000 | 16,575,000 | 40,608,000 | 27,911,000 | 29,625,000 | 32,445,000 | 45,275,000 | 10,651,000 | 4,711,000 | 6,519,000 | 5,373,000 | 4,116,000 | 4,025,000 | 4,182,000 | 5,742,000 | 5,246,000 | 9,580,000 | 13,594,000 | 14,298,000 | 13,385,000 | 13,381,000 | 14,128,000 | 16,227,000 | 15,713,000 | 24,423,000 | 28,588,000 | 26,651,000 | 74,831,000 | 38,854,000 | 82,429,000 |
| selling, general and administrative – related parties | 476,000 | 677,000 | |||||||||||||||||||||||||||||||||||||||
| total operating costs and expenses | 97,710,000 | 80,946,000 | 76,952,000 | 86,359,000 | 100,380,000 | ||||||||||||||||||||||||||||||||||||
| income from operations | -71,285,000 | -64,429,000 | -69,400,000 | -80,253,000 | -99,333,000 | -95,196,000 | -85,389,000 | -80,136,000 | -85,145,000 | -111,580,000 | -84,900,000 | -90,804,000 | -79,622,000 | -95,972,000 | -79,274,000 | -78,836,000 | -85,906,000 | -86,264,000 | -30,886,000 | -21,927,000 | -20,227,000 | -18,586,000 | -16,111,000 | -16,065,000 | -17,296,000 | -18,335,000 | -17,719,000 | -24,108,000 | -28,278,000 | -28,284,000 | -25,394,000 | -24,442,000 | -23,820,000 | -25,464,000 | -25,144,000 | -32,775,000 | -34,965,000 | -31,589,000 | -79,923,000 | -42,794,000 | -84,083,000 |
| yoy | -28.24% | -32.32% | -18.72% | 0.15% | 16.66% | -14.68% | 0.58% | -11.75% | 6.94% | 16.26% | 7.10% | 15.18% | -7.31% | 11.25% | 156.67% | 259.54% | 324.71% | 364.13% | 91.71% | 36.49% | 16.95% | 1.37% | -9.08% | -33.36% | -38.84% | -35.18% | -30.22% | -1.37% | 18.72% | 11.07% | 0.99% | -25.42% | -31.87% | -19.39% | -68.54% | -23.41% | -58.42% | ||||
| qoq | 10.64% | -7.16% | -13.52% | -19.21% | 4.35% | 11.49% | 6.56% | -5.88% | -23.69% | 31.43% | -6.50% | 14.04% | -17.04% | 21.06% | 0.56% | -8.23% | -0.42% | 179.30% | 40.86% | 8.40% | 8.83% | 15.36% | 0.29% | -7.12% | -5.67% | 3.48% | -26.50% | -14.75% | -0.02% | 11.38% | 3.89% | 2.61% | -6.46% | 1.27% | -23.28% | -6.26% | 10.69% | -60.48% | 86.76% | -49.11% | |
| operating margin % | -237990.00% | -61430.94% | -97726.83% | -207670.73% | -30994.44% | -116301.37% | -76952.54% | -227491.43% | -685514.29% | -20326.67% | -119448.48% | -25341.00% | -62060.43% | -147076.19% | -32245.59% | -2022700.00% | -88504.76% | -179011.11% | -133875.00% | -101741.18% | -366700.00% | -253128.57% | -77767.74% | -706950.00% | -565680.00% | -211616.67% | -305525.00% | -170142.86% | -231490.91% | -179600.00% | -273125.00% | -291375.00% | -526483.33% | -570878.57% | -427940.00% | -92398.90% | |||||
| other income | -278,000 | -41,000 | 10,000 | 12,000 | -17,000 | -20,000 | -71,000 | -1,047,000 | -28,000 | -1,077,000 | -923,000 | 6,000 | 185,000 | -4,000 | -59,000 | -38,000 | 277,000 | 13,000 | -1,272,000 | 96,000 | 67,000 | 32,000 | 112,000 | 56,000 | 83,000 | 47,000 | -19,000 | 47,000 | 39,000 | 169,000 | 244,000 | 87,000 | -283,000 | 109,000 | -1,000 | 60,000 | 1,000 | 28,000 | -87,000 | 61,000 | |
| interest and investment income | 1,153,000 | 887,000 | 1,187,000 | 1,798,000 | 1,891,000 | 3,099,000 | 484,000 | 35,000 | -61,000 | 673,000 | -3,813,000 | 857,000 | -1,800,000 | 1,666,000 | -6,926,000 | -5,941,000 | -177,000 | 8,944,000 | |||||||||||||||||||||||
| change in fair value of related-party convertible note | 1,169,000 | -42,582,000 | |||||||||||||||||||||||||||||||||||||||
| interest expense – related party | -15,474,000 | -15,313,000 | |||||||||||||||||||||||||||||||||||||||
| interest expense related to revenue interest liability | -13,405,000 | -13,534,000 | -11,503,000 | -10,925,000 | -9,225,000 | -8,004,000 | |||||||||||||||||||||||||||||||||||
| change in fair value of derivative liabilities | 1,931,000 | 5,578,000 | -6,607,000 | 1,614,000 | 21,194,000 | -2,724,000 | |||||||||||||||||||||||||||||||||||
| change in fair value of warrant liabilities | 3,889,000 | -448,000 | 9,733,000 | 31,324,000 | -19,300,000 | -1,802,000 | -79,400,000 | 14,265,000 | -10,019,000 | 27,554,000 | |||||||||||||||||||||||||||||||
| interest expense | -5,000 | -18,000 | -26,071,000 | -29,322,000 | -29,794,000 | -29,483,000 | -32,126,000 | -35,021,000 | -32,235,000 | -29,816,000 | -28,562,000 | -16,764,000 | -9,698,000 | -8,491,000 | -4,490,000 | -3,614,000 | -3,577,000 | -3,168,000 | -22,000 | -9,000 | -3,000 | -7,000 | -11,000 | -5,000 | -3,000 | -145,000 | -149,000 | -106,000 | -33,000 | -34,000 | -393,000 | -154,000 | -37,000 | -37,000 | -29,000 | ||||||
| total other income | -21,020,000 | -65,471,000 | 10,221,000 | -5,499,000 | -35,251,000 | -38,934,000 | -148,065,000 | -15,506,000 | -53,068,000 | -5,003,000 | -23,392,000 | -20,357,000 | -15,213,000 | -7,026,000 | -12,278,000 | -9,593,000 | -3,477,000 | 5,789,000 | -1,247,000 | 153,000 | 139,000 | 203,000 | 407,000 | 484,000 | 616,000 | 414,000 | 251,000 | 345,000 | 423,000 | 641,000 | 735,000 | 374,000 | 244,000 | 851,000 | 757,000 | 826,000 | 740,000 | 796,000 | -275,250 | 145,000 | |
| income before income taxes and noncontrolling interests | -92,305,000 | -129,900,000 | -59,179,000 | -85,752,000 | -134,584,000 | -134,130,000 | -233,454,000 | -95,642,000 | -138,213,000 | -116,583,000 | -108,292,000 | -111,161,000 | -94,835,000 | -102,998,000 | -91,552,000 | -88,429,000 | -89,383,000 | -80,475,000 | |||||||||||||||||||||||
| income tax expense | -269,000 | -2,000 | -6,000 | 250 | |||||||||||||||||||||||||||||||||||||
| net income | -92,574,000 | -129,666,000 | -59,179,000 | -85,752,000 | -134,584,000 | -134,130,000 | -233,414,000 | -95,642,000 | -138,213,000 | -116,583,000 | -108,326,000 | -111,161,000 | -94,835,000 | -102,998,000 | -91,553,000 | -88,429,000 | -89,385,000 | -80,481,000 | -32,132,000 | -21,776,000 | -20,092,000 | -18,383,000 | -15,641,000 | -15,581,000 | -16,682,000 | -17,885,000 | -17,340,000 | -23,635,000 | -27,732,000 | -27,519,000 | -24,487,000 | -23,969,000 | -23,452,000 | -24,515,000 | -24,238,000 | -31,897,000 | -33,997,000 | -30,650,000 | -76,821,000 | -42,649,000 | -84,581,000 |
| yoy | -31.21% | -3.33% | -74.65% | -10.34% | -2.63% | 15.05% | 115.47% | -13.96% | 45.74% | 13.19% | 18.32% | 25.71% | 6.10% | 27.98% | 184.93% | 306.08% | 344.88% | 337.80% | 105.43% | 39.76% | 20.44% | 2.78% | -9.80% | -34.08% | -39.85% | -35.01% | -29.19% | -1.39% | 18.25% | 12.25% | 1.03% | -24.86% | -31.02% | -20.02% | -68.45% | -25.21% | -59.81% | ||||
| qoq | -28.61% | 119.11% | -30.99% | -36.28% | 0.34% | -42.54% | 144.05% | -30.80% | 18.55% | 7.62% | -2.55% | 17.22% | -7.93% | 12.50% | 3.53% | -1.07% | 11.06% | 150.47% | 47.56% | 8.38% | 9.30% | 17.53% | 0.39% | -6.60% | -6.73% | 3.14% | -26.63% | -14.77% | 0.77% | 12.38% | 2.16% | 2.20% | -4.34% | 1.14% | -24.01% | -6.18% | 10.92% | -60.10% | 80.12% | -49.58% | |
| net income margin % | -335325.00% | -167923.74% | -116636.59% | -337104.88% | -32384.17% | -148391.78% | -94204.24% | -270957.14% | -735700.00% | -23475.13% | -133983.33% | -26367.26% | -57900.00% | -153009.52% | -32023.53% | -2009200.00% | -87538.10% | -173788.89% | -129841.67% | -98129.41% | -357700.00% | -247714.29% | -76241.94% | -693300.00% | -550380.00% | -204058.33% | -299612.50% | -167514.29% | -222863.64% | -173128.57% | -265808.33% | -283308.33% | -510833.33% | -548721.43% | -426490.00% | -92946.15% | |||||
| net income attributable to noncontrolling interests, net of tax | -19,000 | -20,000 | -17,000 | -23,000 | -20,000 | -21,000 | -22,000 | -60,000 | -334,000 | -240,000 | -111,000 | -223,000 | -247,000 | -172,000 | -294,000 | -800,000 | -1,097,000 | -867,000 | |||||||||||||||||||||||
| net income attributable to immunitybio common stockholders | -92,555,000 | -129,646,000 | -59,162,000 | -85,729,000 | -134,564,000 | -134,109,000 | -233,392,000 | -95,582,000 | -137,879,000 | -116,343,000 | -108,215,000 | -110,938,000 | -94,588,000 | -102,826,000 | -91,259,000 | -87,629,000 | -88,288,000 | -79,614,000 | |||||||||||||||||||||||
| net income per immunitybio common share – basic | -100 | -150 | -70 | -120 | -260 | ||||||||||||||||||||||||||||||||||||
| net income per immunitybio common share – diluted | -100 | -150 | -90 | -140 | -260 | ||||||||||||||||||||||||||||||||||||
| weighted-average number of common shares used in computing net income per share – basic | 888,216 | 853,162 | 697,312 | 695,895 | |||||||||||||||||||||||||||||||||||||
| weighted-average number of common shares used in computing net income per share – diluted | 888,216 | 853,162 | 700,443 | 697,961 | |||||||||||||||||||||||||||||||||||||
| income tax benefit | 234,000 | -1,000 | 1,000 | -2,000 | -4,000 | 63,000 | -2,000 | 36,000 | 128,000 | 128,000 | 123,000 | -124,000 | -172,000 | -99,000 | -124,000 | -98,000 | |||||||||||||||||||||||||
| cost of product revenue | |||||||||||||||||||||||||||||||||||||||||
| loss on equity method investment | -1,255,000 | -3,957,000 | -2,337,000 | -3,554,000 | -4,456,000 | -3,900,000 | -197,000 | ||||||||||||||||||||||||||||||||||
| net income per immunitybio common share – basic and diluted | -200 | -200 | -380 | -190 | -320 | -270 | -270 | -280 | -240 | -165 | -220 | -230 | -210 | ||||||||||||||||||||||||||||
| weighted-average number of common shares used in computing net income per share – basic and diluted | 686,938,120 | 672,831,258 | 508,635,592 | 498,375,316 | 437,456,657 | 428,381,485 | 399,900,374 | 400,059,707 | 397,991,630 | 397,882,441 | 389,234,156 | 391,853,623 | 384,820,486 | 382,741,464 | |||||||||||||||||||||||||||
| operating expenses: | |||||||||||||||||||||||||||||||||||||||||
| total operating expenses | 95,236,000 | 85,528,000 | 80,218,000 | 85,186,000 | 111,940,000 | 84,973,000 | 90,922,000 | 79,657,000 | 95,986,000 | 79,664,000 | 78,902,000 | 86,245,000 | 86,403,000 | 30,907,000 | 21,995,000 | 20,228,000 | 18,607,000 | 16,120,000 | 16,077,000 | 17,313,000 | 18,340,000 | 17,726,000 | 24,139,000 | 28,282,000 | 28,289,000 | 25,406,000 | 24,450,000 | 23,834,000 | 25,475,000 | 25,158,000 | 32,787,000 | 34,977,000 | 31,595,000 | 79,937,000 | 42,804,000 | 84,174,000 | |||||
| other income, net: | |||||||||||||||||||||||||||||||||||||||||
| change in fair value of convertible note | 187,250 | 7,517,000 | -6,768,000 | ||||||||||||||||||||||||||||||||||||||
| impairment of intangible assets | |||||||||||||||||||||||||||||||||||||||||
| other income: | |||||||||||||||||||||||||||||||||||||||||
| investment income | 47,000 | 66,000 | 75,000 | 178,000 | 306,000 | 433,000 | 533,000 | 370,000 | 415,000 | 447,000 | 490,000 | 505,000 | 525,000 | 680,000 | 681,000 | 779,000 | 795,000 | 795,000 | 739,000 | 768,000 | |||||||||||||||||||||
| income before income taxes | -32,133,000 | -21,774,000 | -20,088,000 | -18,383,000 | -15,704,000 | -15,581,000 | -16,680,000 | -17,921,000 | -17,468,000 | -23,763,000 | -27,855,000 | -27,643,000 | -24,659,000 | -24,068,000 | -23,576,000 | -24,613,000 | -24,387,000 | -31,949,000 | -34,225,000 | -30,793,000 | -77,123,000 | -42,649,000 | -84,581,000 | ||||||||||||||||||
| net income per share | |||||||||||||||||||||||||||||||||||||||||
| basic and diluted | -0.3 | -0.2 | -0.2 | -0.19 | -0.16 | -0.16 | -0.17 | -0.22 | -0.22 | -0.3 | -0.35 | -0.35 | -0.31 | -0.3 | -0.29 | -0.3 | -0.29 | -0.39 | -0.41 | -0.38 | -0.97 | -0.55 | -1.29 | ||||||||||||||||||
| weighted-average number of shares during the period: | |||||||||||||||||||||||||||||||||||||||||
| basic and diluted | 103,550,936 | 108,246,579 | 98,769,687 | 98,472,641 | 94,210,087 | 98,331,695 | 98,594,355 | 81,261,302 | 79,132,220 | 79,204,765 | 79,107,208 | 79,036,614 | 80,583,910 | 79,440,591 | 81,440,816 | 82,138,438 | 81,979,005 | 82,154,219 | 81,959,248 | 81,574,709 | 71,519,609 | 77,837,586 | 65,789,041 | ||||||||||||||||||
| change in fair value of warrant liability | |||||||||||||||||||||||||||||||||||||||||
| income tax (benefit) expense | -149,000 | -52,000 | -228,000 | -143,000 | |||||||||||||||||||||||||||||||||||||
| interest income | 25,250 | 84,000 | -15,000 | ||||||||||||||||||||||||||||||||||||||
| fair value adjustment | -341,500 | -483,000 |
We provide you with 20 years income statements for ImmunityBio stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ImmunityBio stock. Explore the full financial landscape of ImmunityBio stock with our expertly curated income statements.
The information provided in this report about ImmunityBio stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.